EUCTR2007-002542-38-DE进行中（未招募）不适用
A randomized, double blind, placebo controlled, parallel group design study to explore the efficacy, safety and tolerability of AEB071 in patients with active, moderate to severe ulcerative colitis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females 18-75 years of age with an established diagnosis of ulcerative colitis are eligible for the study.
- •2. Female patients of child-bearing potential must be concurrently using two acceptable methods of contraception, (e.g. intra-uterine device plus condom, spermicidal gel plus condom, diaphragma plus condom, etc.) from the time of screening and for the duration of the study, through study completion and for 1 month following study completion.
- •3. Patients must have active, moderate to severe disease with a Partial Mayo Score between 5 and 10 (inclusive), with a score of at least 2 on either stool frequency or rectal bleeding and a Modified Baron Score of at least 2 upon endoscopic examination with the disease extending at least 25 cm from the anal verge.
- •4. Patients must have responded poorly to conventional therapy. Poor response is considered to be any of the following:
- •the continuous requirement for intermittent, oral steroid therapy of more than 20 mg methylprednisolone or equivalent per day for more than 3 months (including steroid dependence defined as relapse within 3 months after stopping).
- •the requirement for = 2 g mesalamine per day.
- •the failure to remain symptom-free on maintenance medication of azathioprine or 6-
- •mercaptopurin (an adequate course is considered to be at least 12 weeks of treatment).
- •Patients that do not tolerate mesalamine or steroid therapy will also be included. Doses of steroids and mesalamine, where topical therapy is not allowed, will be frozen at the time of screening and may be continued unchanged. The maximum allowed daily steroid dose is 20 mg methylprednisolone (or equivalent steroid dose). Other maintenance medications like azathioprine or 6-mercaptopurin will be continued unchanged throughout the study period.
- •5. Patients must be able to communicate well with the investigator, to understand and comply with the requirements of the study and to understand and sign written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous treatment with biologics (e.g. anti TNF-a) within the last 3 months or use of any other investigational drug within the previous 1 month.
- •2. Hypersensitivity to AEB071 compound.
- •3. Weight of less than 50 kg or more than 150 kg.
- •4. Ongoing treatment with antibiotics, cyclosporine, methotrexate, tacrolimus or rectally administered corticosteroid or 5-aminosalicylate containing medication. Eligible patients must have stopped cyclosporine, methotrexate and tacrolimus at least 8 weeks and antibiotics and rectal topical therapy at least 2 weeks prior to study entry.
- •5. Patients with active or history of clinically significant cardiac abnormalities, for example:
- •Patients requiring drugs with QT-prolonging properties (e.g. antiarrhythmic drugs, such as amiodarone, sotalol, dofetilide, quinidine, procainamide, disopyramide).
- •Patients with sustained heart rate <50 bpm or >90 bpm after resting in supine position for 5 minutes.
- •Patients with hypokalemia, QTc >470msec, long QT-syndrome (own or with a family history) or with a family history of sudden unexplained death. •Patients with implanted cardiac pacemaker or defibrillator.
- •Patients with left branch bundle block (LBBB), and patients with known history of congestive heart failure (NYHA class II to IV) or known left-ventricular dysfunction (LVEF < 45%).
- •History of tachyarrhythmia e.g., supraventricular tachycardia, atrial flutter, atrial fibrillation, ventricular tachycardia, ventricular flutter, ventricular fibrillation.
- •History of myocardial infarction within the previous 12 months; uncontrolled or unstable angina pectoris.
- •History of syncope.
- •6. Patients who are requiring the administration of strongly interacting drugs of the CYP450 3A4/5 system (See Appendix 6).
- •7. Positive results for the detection of enteropathogens (including Salmonella, Yersinia, Shigella, Camplylobacter, EHEC and C. difficile).
- •8. Laboratory findings showing:
- •Aspartate aminotransferase, alanine aminotransferase and bilirubin higher than 3 times the upper limit of normal,
- •Alkaline phosphatase higher than 2 times the upper limit of normal,
- •Absolute neutrophil count of <1,500/mm3, an absolute leukocyte count <2,500/mm3 or platelets <75,000/mm3.
- •9. Patients who have been diagnosed with primary sclerosing cholangitis are excluded from the study.
- •10. History of renal trauma, glomerulonephritis or patients with one kidney. Presence of clinically significant proteinuria, active sediments,
- •casts or WBCs in urine.
- •11. Clinical signs and symptoms of toxic megacolon.
- •12. Presence or history of major chronic inflammatory autoimmune diseases, e.g. SLE.
- •13. History of alcohol or drug abuse.
- •14. Pregnant or breastfeeding women are excluded.
- •15. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.
- •16. Administration of live vaccines within 6 months prior to dosing.
- •17. A positive HIV (ELISA and Western blot) test result, Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
- •18. Significant illness within the two weeks prior to dosing or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study.
- •19. History of malignancy (other than basal cell carcinoma or adequately treated carcinoma-in-situ of the cervix).
- •20. Presence or history of underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointe
研究者
相似试验
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors - Permanent Atrial fibriLLAtion outcome Study using Dronedarone on top of standard therapy (PALLAS)MedDRA version: 14.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial FibrillationEUCTR2010-019791-73-DESanofi-aventis recherche & développement10,800
进行中（未招募）
1 期
Investigate the safety and efficacy of study drug ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have failed to other treatments.Moderate to Severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10066678Term: Acute ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-003558-26-CZABIVAX232
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, parallel groups, pilot study to assess the effects of two new nail lacquers, cyclosporine 5% and calcipotriol 0.005%, in the treatment of nail psoriasis - NDail psoriasisMedDRA version: 9.1Level: LLTClassification code 10028703EUCTR2010-019706-16-ITPOLICHEM
进行中（未招募）
不适用
A randomized, double blind, placebo controlled, parallel group, multicenter study of the safety and response rate of 3 subcutaneously administered doses of 5x10E7pfu RO5217790 in patients with high grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infectioHigh grade cervical intraepithelial neoplasia grade 2 or 3 associated with High Risk HPV infectionMedDRA version: 9.1Level: LLTClassification code 10049701Term: Cervical intraepithelial neoplasia IIMedDRA version: 9.1Level: LLTClassification code 10049702Term: Cervical intraepithelial neoplasia IIIEUCTR2008-006946-24-DEF. Hoffmann-La Roche Ltd200
进行中（未招募）
不适用
A clinical study evaluating two different nail lacquers containing cyclosporine 5% and calcipotriol 0.005% in the treatment of nail psoriasis. A placebo (no active compound) will be used as control. Nor the investigator nor the patient will know the treatment applied.ail psoriasis of the nail matrix and / or the nail bed at fingernails (at least one should be affected)EUCTR2010-019706-16-LVPolichem SA75